Loading organizations...
§ Venture Capital · No. 6 Xiangyun Road, Wujin District, Changzhou City, Jiangsu Province, China
Tuobang Capital operates as a venture capital firm based in China, specializing in providing essential capital and strategic support to emerging enterprises. The firm focuses on identifying and investing in innovative life science companies, playing a key role in incubating advancements within this critical sector. Its approach involves supporting firms through their growth stages, fostering the development of novel solutions and technologies.
The firm was established to address a clear market need for dedicated investment within the burgeoning life science landscape in China. While specific founding details and individual founders are not publicly detailed, its formation reflects a strategic commitment to nurturing early-stage ventures that possess significant potential for scientific and commercial impact. Its inception underscores a broader trend of targeted capital allocation to high-growth, specialized industries.
Tuobang Capital primarily serves a portfolio of promising life science companies, which leverage its investments to drive research, development, and market penetration. The firm's overarching vision is to catalyze innovation and accelerate the growth of the life science industry within China, ultimately contributing to a more robust and advanced ecosystem for health and biotechnology solutions. It aims to be a foundational partner for companies shaping the future of medicine and related fields.
Tuobang Capital has 1 tracked investment across 1 company. The latest tracked deal is $42.0M Other Equity in NuProbe in January 2021.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 11, 2021 | NuProbe | $42.0M Other Equity | WEN Chen | Hongshan Capital Group (Sequoia Capital China), Juming Capital, Panlin Capital, Ruomu Capital, Serica Partners, Taifu Capital |